<?xml version="1.0" encoding="UTF-8"?>
<p id="Par63">Currently, Adamantanes have no action against influenza B virus (IBV) and NA inhibitors have shown activity against both IAV and IBV pathogens [
 <xref ref-type="bibr" rid="CR95">95</xref>]. Available therapeutic weapons have limitations, including resistance to highly pathogenic viral strain, prohibitive cost, viral mutation, lack of availability of the desired vaccine due to the time lag between vaccine development and adverse side effects. Unfortunately, none of these drugs have, until recently, been fully capable of impressing on a new pandemic strain of H1N1 influenza to eradicate infection.
</p>
